Management

This page includes content on healthcare management, including health system, hospital, department and clinic business management and administration. Areas of focus are on cardiology and radiology department business administration. Subcategories covered in this section include healthcare economics, reimbursement, leadership, mergers and acquisitions, policy and regulations, practice management, quality, staffing, and supply chain.

RSS icon

Prototype of portable retina camera simplifies eye exams

Researchers from the University of Illinois at Chicago College of Medicine and Massachusetts Eye and Ear at Harvard Medical School have developed a portable retina camera to be used in eye exams without the need for pupil-dilating eye drops.

Thumbnail

Poll: Parents take different paths to expert care for sick children

Having a sick child is stressful for any parent—with many of them seeking medical advice as soon as possible. The annual C.S. Mott Children’s Hospital National Poll examined the approaches parents take to get medical advice quickly and safely for their children. 

ACA replacement set for vote in House on March 23

The Republican-sponsored replacement for the Affordable Care Act (ACA), the American Health Care Act (AHCA), will get a vote in the full U.S. House on March 23, despite doubts that it has enough votes to pass.

Former Anthem lobbyist to be nominated to run DOJ’s antitrust division

The specific division of the U.S. Department of Justice that fought Anthem’s $54 billion acquisition of Cigna—and which the insurers is still pushing to approve the merger over antitrust concerns—could be run by a former Anthem lobbyist.

Thumbnail

Mayo Clinic facing state review for prioritizing privately insured patients

Mayo Clinic is being reviewed by the Minnesota Department of Human Services (DHS) for possibly breaking civil and human rights laws after comments from CEO John Noseworthy, MD, encouraging employees to prioritize commercially insured patients over Medicare and Medicaid beneficiaries.

MGMA to CMS: Where are the MIPS eligibility notifications?

The Medical Group Management Association (MGMA) has asked newly confirmed CMS Administrator Seema Verma to quickly release overdue eligibility information for the Merit-based Incentive Payment System (MIPS), one of two new payment tracks implemented as part of the Medicare Access and CHIP Reauthorization Act (MACRA). 

Thumbnail

Durbin: No Senate Dems will vote for AHCA, but open to discussion on drug prices

It’s the job of Sen. Dick Durbin, D-Illinois, as the Senate minority whip to know where every member of his caucus stands on major pieces of legislation. When it comes to the American Health Care Act (AHCA), the Republican-sponsored plan to repeal and replace the Affordable Care Act (ACA), he said to HealthExec “no” Democrats in the chamber would support the bill as-is.

ACOs saved Medicare Part D $345 per patient

Spending on Medicare Part D subscribers was $345 lower per patient when that beneficiary was aligned with an accountable care organization (ACO), according to an analysis from the University of Pittsburgh School of Public Health.

Displaying 4849 - 4856 of 6646

Around the web

Cardiovascular Business
Q&A: Why are cardiovascular devices involved in so many recalls? FDA policies may be to blame

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Cardiovascular Business
Cardiologist compensation still rising, especially in invasive and interventional cardiology

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Cardiovascular Business
FDA’s tirzepatide decision creates uncertainty for patients—and leads to a lawsuit

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Design by Adaptive Theme
Trimed Popup
Trimed Popup